[{"id":"0259c6da-60cc-4165-a7fc-adacc10727ab","acronym":"NCI-2018-00438","url":"https://clinicaltrials.gov/study/NCT03552471","created_at":"2021-01-18T17:29:09.671Z","updated_at":"2025-02-25T15:10:50.793Z","phase":"Phase 1","brief_title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03552471 - NCI-2018-00438","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 06/24/2022","primary_completion_date":" 06/24/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2025-02-13"},{"id":"aba0c228-f58a-4822-93bc-d017af087c85","acronym":"","url":"https://clinicaltrials.gov/study/NCT05887609","created_at":"2023-06-05T15:07:17.114Z","updated_at":"2025-02-25T15:13:30.894Z","phase":"Phase 2","brief_title":"An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib","source_id_and_acronym":"NCT05887609","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"96f0f596-bee1-42fc-9dcc-41fcf8f78f40","acronym":"SL03-OHD-105","url":"https://clinicaltrials.gov/study/NCT05483933","created_at":"2022-08-02T12:55:49.417Z","updated_at":"2025-02-25T15:27:30.695Z","phase":"Phase 1","brief_title":"Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers","source_id_and_acronym":"NCT05483933 - SL03-OHD-105","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-11"},{"id":"809acd3d-0f20-4fcc-9b3f-5f01fafa10a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05456685","created_at":"2022-07-13T12:56:36.433Z","updated_at":"2025-02-25T17:31:27.306Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05456685","lead_sponsor":"AbbVie","biomarkers":" FOLR1 • BRCA","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 09/28/2022","start_date":" 09/28/2022","primary_txt":" Primary completion: 05/12/2026","primary_completion_date":" 05/12/2026","study_txt":" Completion: 05/12/2026","study_completion_date":" 05/12/2026","last_update_posted":"2025-01-30"},{"id":"73e3eec7-4518-48c4-b46f-3dd2b5e30704","acronym":"","url":"https://clinicaltrials.gov/study/NCT03835819","created_at":"2021-01-18T18:56:17.574Z","updated_at":"2025-02-25T16:08:53.728Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)","source_id_and_acronym":"NCT03835819","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" FOLR1 • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSH6 expression","tags":["FOLR1 • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 06/04/2024","primary_completion_date":" 06/04/2024","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-11-08"},{"id":"1191eb18-5a65-4cb1-bbf7-bb4841595232","acronym":"","url":"https://clinicaltrials.gov/study/NCT03832361","created_at":"2025-02-26T08:44:50.615Z","updated_at":"2025-02-26T08:44:50.615Z","phase":"Phase 2","brief_title":"Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer","source_id_and_acronym":"NCT03832361","lead_sponsor":"Alessandro Santin","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/15/2020","start_date":" 07/15/2020","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-08-20"},{"id":"5e4a1b0f-c052-4ea3-b52c-56f571a546e9","acronym":"KEYNOTE PN409","url":"https://clinicaltrials.gov/study/NCT02606305","created_at":"2024-02-04T01:25:14.975Z","updated_at":"2024-07-02T16:34:25.701Z","phase":"Phase 1/2","brief_title":"Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02606305 - KEYNOTE PN409","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 264","initiation":"Initiation: 03/02/2016","start_date":" 03/02/2016","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 03/12/2021","study_completion_date":" 03/12/2021","last_update_posted":"2024-06-14"},{"id":"023cf6d7-38d4-4089-89bb-ebee230e66e8","acronym":"GLORIOSA","url":"https://clinicaltrials.gov/study/NCT05445778","created_at":"2022-07-06T15:54:42.215Z","updated_at":"2024-07-02T16:34:26.631Z","phase":"Phase 3","brief_title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)","source_id_and_acronym":"NCT05445778 - GLORIOSA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA • MUC16","pipe":" | ","alterations":" FOLR1 expression • MUC16 elevation","tags":["FOLR1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 418","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-06-13"},{"id":"85edd770-3ac8-453d-88dc-75e0a0a175d3","acronym":"PICCOLO","url":"https://clinicaltrials.gov/study/NCT05041257","created_at":"2021-09-13T15:55:27.708Z","updated_at":"2024-07-02T16:35:08.475Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)","source_id_and_acronym":"NCT05041257 - PICCOLO","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA","pipe":" | ","alterations":" FOLR1 expression • BRCA mutation","tags":["FOLR1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 01/17/2024","primary_completion_date":" 01/17/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-04-22"},{"id":"89ab6e89-05c5-41d2-9c7b-7bfb72aee4a6","acronym":"NCI-2016-01913","url":"https://clinicaltrials.gov/study/NCT02996825","created_at":"2021-01-17T17:41:57.107Z","updated_at":"2024-07-02T16:35:12.045Z","phase":"Phase 1","brief_title":"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer","source_id_and_acronym":"NCT02996825 - NCI-2016-01913","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR • MUC16","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Elahere (mirvetuximab soravtansine-gynx) • liposomal gemcitabine (FF-10832)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/22/2017","start_date":" 03/22/2017","primary_txt":" Primary completion: 02/09/2024","primary_completion_date":" 02/09/2024","study_txt":" Completion: 02/09/2024","study_completion_date":" 02/09/2024","last_update_posted":"2024-04-02"},{"id":"a012529c-d433-4cc1-950b-b069e61ba45c","acronym":"MIROVA","url":"https://clinicaltrials.gov/study/NCT04274426","created_at":"2021-01-18T20:45:40.588Z","updated_at":"2024-07-02T16:35:23.352Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04274426 - MIROVA","lead_sponsor":"AGO Research GmbH","biomarkers":" BRCA1 • BRCA2 • FOLR1 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA wild-type","tags":["BRCA1 • BRCA2 • FOLR1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-15"},{"id":"ea2b2cd9-de2b-48c3-a36f-f7e33e0ebe95","acronym":"","url":"https://clinicaltrials.gov/study/NCT04606914","created_at":"2021-01-19T20:31:38.308Z","updated_at":"2024-07-02T16:35:27.611Z","phase":"Phase 2","brief_title":"Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT04606914","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" BRCA","pipe":" | ","alterations":" FOLR1 expression","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/27/2021","start_date":" 05/27/2021","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2023-11-30"},{"id":"7ea7b76e-29f6-4753-a54f-be730ae868af","acronym":"MIRASOL","url":"https://clinicaltrials.gov/study/NCT04209855","created_at":"2021-01-18T20:30:11.495Z","updated_at":"2024-07-02T16:35:54.021Z","phase":"Phase 3","brief_title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","source_id_and_acronym":"NCT04209855 - MIRASOL","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-03-06"},{"id":"9be2dc89-a060-4c39-916d-51ddaf88fadd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05622890","created_at":"2022-11-21T14:57:00.361Z","updated_at":"2024-07-02T16:36:00.129Z","phase":"Phase 3","brief_title":"A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05622890","lead_sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","biomarkers":" FOLR1 • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-11-21"},{"id":"ab1ca9de-5568-498f-b59d-7da3aaee923b","acronym":"IMGN-0401","url":"https://clinicaltrials.gov/study/NCT01609556","created_at":"2021-02-17T19:52:44.463Z","updated_at":"2024-07-02T16:36:34.499Z","phase":"Phase 1","brief_title":"First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors","source_id_and_acronym":"NCT01609556 - IMGN-0401","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 06/28/2012","start_date":" 06/28/2012","primary_txt":" Primary completion: 03/19/2018","primary_completion_date":" 03/19/2018","study_txt":" Completion: 03/19/2018","study_completion_date":" 03/19/2018","last_update_posted":"2021-02-17"},{"id":"7d05a8fe-d87f-48ee-a459-03f133616814","acronym":"","url":"https://clinicaltrials.gov/study/NCT03106077","created_at":"2021-01-18T15:18:09.965Z","updated_at":"2024-07-02T16:36:37.925Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT03106077","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 06/05/2017","start_date":" 06/05/2017","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2019","study_completion_date":" 10/01/2019","last_update_posted":"2020-12-02"},{"id":"6ea69e56-9836-479f-95d8-b31e44da4f12","acronym":"FORWARD I","url":"https://clinicaltrials.gov/study/NCT02631876","created_at":"2021-01-18T12:47:56.060Z","updated_at":"2024-07-02T16:36:40.091Z","phase":"Phase 3","brief_title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","source_id_and_acronym":"NCT02631876 - FORWARD I","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 366","initiation":"Initiation: 03/02/2016","start_date":" 03/02/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-10-14"},{"id":"f9eb3f7a-1417-4158-bc47-3ab049b91f3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03836157","created_at":"2021-01-18T18:56:23.826Z","updated_at":"2024-07-02T16:36:58.578Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer","source_id_and_acronym":"NCT03836157","lead_sponsor":"University of Oklahoma","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/31/2019","start_date":" 05/31/2019","primary_txt":" Primary completion: 11/30/2021","primary_completion_date":" 11/30/2021","study_txt":" Completion: 05/01/2022","study_completion_date":" 05/01/2022","last_update_posted":"2019-06-27"}]